HIV-1 transactivator.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

HIV-1 transactivator.

Harvard AIDS Inst Ser; 1:43-310 1991. Unique Identifier : AIDSLINE ICDB/93686277
Anonymous; No affiliation given

Abstract: Transcription of the HIV genome proceeds in distinct kinetic phases. Initially, short, multiply spliced mRNAs, which encode the viral regulatory proteins tat and rev, are expressed, whereas, late in infection production switches to full-length, unspliced transcripts that act both as the virion RNA and the mRNA for the gag-pol polyprotein. HIV-1 transactivator is reviewed in the following chapters: RNA interactions of the tat and rev proteins of HIV-1; the role of the TAR region and tat protein in HIV-directed gene expression; RNA-protein interactions required for regulation of HIV gene expression; cellular factors involved in regulating HIV gene expression; biochemical characterization of REV-RRE interaction; analysis of the structure of the HIV-1 tat protein; mechanisms of regulation of tat and rev; genome organization and regulation of HIV-1 expression; mechanism of function of the rex protein of HTLV-1; tat-mediated trans-activation as a presplicing event requiring a functional HIV-1 TATAA element; analysis of the TAT/TAR interaction in Xenopus oocytes; transcriptional regulation of HIV; functional topography of lentivirus tat proteins defined by domain switching; nucleolar targeting singles of HIV; characterization of the specific interaction between TAT and TAR RNA; and the exogenous trans-activation activity of HIV-1 tat.

Keywords: Animal Gene Expression Regulation, Viral Gene Products, rev/METABOLISM Gene Products, rex/METABOLISM Gene Products, tat/METABOLISM Genes, Viral HIV-1/*GENETICS HTLV-I/METABOLISM RNA Splicing RNA, Viral/METABOLISM *Trans-Activators Transcription, Genetic Viral Proteins/METABOLISM Xenopus MONOGRAPH
930228
M9320883

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .